Barney Isaac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Barney Isaac has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Devasahayam Jesudas Christopher
Christian Medical College, Vellore, India
6 shared publications Balamugesh Thangakunam
Department of Pulmonary Medicine, Christian Medical College, Vellore (Tamil Nadu), India
3 shared publications- Balamugesh Thangakunam
Affiliation Department of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India
3 shared publications Avinash Anil Nair
Department of Respiratory Medicine Christian Medical College Vellore Tamil Nadu India
2 shared publications- Jefferson Daniel
Department of Pulmonary Medicine, Christian Medical College, Vellore, Tamil Nadu, India
2 shared publications Kishore Pichamuthu
Department of Medical ICU, Christian Medical College, Vellore, India
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360678
Interstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study)
Background and objectives: There is limited data on prescription behaviour and compliance with interstitial lung disease (ILD) guidelines among pulmonologists. This study aimed to evaluate ILDs treatment prescription behaviour in India. Methods: Prescriptions of treatment-naive ILD patients from 13 tertiary care hospitals were reviewed and classified as guideline compliant (GCP) or non-compliant (GNCP) for pharmacological and non-pharmacological components. Change in forced vital capacity (FVC), diffusing capacity (DLCO), and six-minute walk distance (6-MWD) at 6 and 12 months were compared between GCP and GNCP. Results: After screening 720 participants, 425 treatment-naïve ILD patients (56.7% female; mean age 51.7 years) were included. Connective tissue associated-ILD (CTD-ILD) was the most common diagnosis (36.2%), followed by hypersensitivity pneumonitis (17.4%), idiopathic pulmonary fibrosis (IPF, 13.9%), interstitial pneumonia with autoimmune features (13.9%), and sarcoidosis (8.2%). GCP rates for ILD specific pharmacotherapy were 83%, 74.7%, and 93.5% for IPF, CTD-ILD, and sarcoidosis, respectively. In IPF, patients with GCP had significantly lower FVC decline at 12 months compared to the GNCP (0.06 L vs. 0.25 L; p = 0.02). There was huge care-gap in non-pharmacological advice with 13.2%, 7.1%, 10.2% and 4.2% of eligible cases were advised vaccination, pulmonary rehabilitation, antigen avoidance, and lung transplantation counselling, respectively. Interpretation and conclusions: India-ILD care study revealed a huge care gap with significantly under-prescription of non-pharmacological components. These results highlight the urgent need for organized implementation strategies including dissemination of guidelines, and a greater emphasis on a structured management protocol that includes both pharmacological and non-pharmacological treatment to optimize outcomes for ILD in India.
- 23 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0360678
Open AccessInterstitial Lung Diseases treatment prescription practices among pulmonologists in India: A prospective multicentre observational study (India-ILD care study)
Background and objectives: There is limited data on prescription behaviour and compliance with interstitial lung disease (ILD) guidelines among pulmonologists. This study aimed to evaluate ILDs treatment prescription behaviour in India. Methods: Prescriptions of treatment-naive ILD patients from 13 tertiary care hospitals were reviewed and classified as guideline compliant (GCP) or non-compliant (GNCP) for pharmacological and non-pharmacological components. Change in forced vital capacity (FVC), diffusing capacity (DLCO), and six-minute walk distance (6-MWD) at 6 and 12 months were compared between GCP and GNCP. Results: After screening 720 participants, 425 treatment-naïve ILD patients (56.7% female; mean age 51.7 years) were included. Connective tissue associated-ILD (CTD-ILD) was the most common diagnosis (36.2%), followed by hypersensitivity pneumonitis (17.4%), idiopathic pulmonary fibrosis (IPF, 13.9%), interstitial pneumonia with autoimmune features (13.9%), and sarcoidosis (8.2%). GCP rates for ILD specific pharmacotherapy were 83%, 74.7%, and 93.5% for IPF, CTD-ILD, and sarcoidosis, respectively. In IPF, patients with GCP had significantly lower FVC decline at 12 months compared to the GNCP (0.06 L vs. 0.25 L; p = 0.02). There was huge care-gap in non-pharmacological advice with 13.2%, 7.1%, 10.2% and 4.2% of eligible cases were advised vaccination, pulmonary rehabilitation, antigen avoidance, and lung transplantation counselling, respectively. Interpretation and conclusions: India-ILD care study revealed a huge care gap with significantly under-prescription of non-pharmacological components. These results highlight the urgent need for organized implementation strategies including dissemination of guidelines, and a greater emphasis on a structured management protocol that includes both pharmacological and non-pharmacological treatment to optimize outcomes for ILD in India.
- 30 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 249, 108467
Effect of eosinophilia on duration of hospital stay in patients admitted with acute exacerbation of chronic obstructive pulmonary disease
- 30 October 2025
- Published by Elsevier in Respiratory Medicine
- Vol. 249, 108467
Effect of eosinophilia on duration of hospital stay in patients admitted with acute exacerbation of chronic obstructive pulmonary disease
- Open Access
- 21 June 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-7
A retrospective analysis of the diagnostic utility of endobronchial ultrasound guided–intranodal forceps biopsy (EBUS-IFB) in the evaluation of mediastinal adenopathy
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the preferred diagnostic modality for evaluating mediastinal lymphadenopathy. However, its diagnostic yield is significantly reduced in conditions such as sarcoidosis, tuberculosis, and lymphoma. To address this limitation, EBUS-guided intranodal forceps biopsy (EBUS-IFB) has been proposed as an adjunct technique to enhance diagnostic accuracy in these challenging cases. This study aimed to evaluate the diagnostic yield of EBUS-IFB in the assessment of mediastinal lymphadenopathy. Methods: We retrospectively reviewed patients with mediastinal lymphadenopathy who underwent EBUS-guided intranodal forceps biopsy (EBUS-IFB). Diagnostic yield was determined using a composite reference standard (CRS), which was considered positive if a definitive diagnosis was established by any of the following: rapid on-site evaluation (ROSE), EBUS-TBNA, EBUS-IFB, bronchial biopsy, or transbronchial lung biopsy. To specifically evaluate the incremental diagnostic yield of EBUS-IFB, cases with non-diagnostic ROSE results were analysed separately. Results: Of the 40 cases with undiagnosed mediastinal lymphadenopathy, CRS was obtained in 31 cases (77.5%), while the remainder were diagnosed as reactive lymphadenopathy. Sampling adequacy was achieved in 39 out of 40 cases (97.5%). The overall diagnostic yield for EBUS-TBNA, EBUS-IFB, and combined EBUS-TBNA along with IFB (combined approach) were 54.8%, 83.9% (p value:0.03), and 90.3% (p value: 0.004) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 29.0% and 35.5% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity EBUS-IFB were 84% and 100% respectively. In subgroup analysis for cases with non-diagnostic ROSE, the diagnostic yield for EBUS-TBNA, EBUS-IFB, and the combined approach (EBUS-TBNA + IFB) were 48.2%, 85.2% (p value: 0.009) and 88.9% (p value: 0.003) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 37.0% and 40.7% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity of EBUS-IFB when ROSE was non-diagnostic were 85.2% and 100% respectively. No major complications were noted. Conclusion: The addition of IFB to routine TBNA significantly improves the diagnostic yield of EBUS, particularly in cases of non-diagnostic ROSE, with no added procedural complications.
- 21 June 2025
- Published by Springer Nature in The Egyptian Journal of Bronchology
- Vol. 19 (1) , 1-7
Open AccessA retrospective analysis of the diagnostic utility of endobronchial ultrasound guided–intranodal forceps biopsy (EBUS-IFB) in the evaluation of mediastinal adenopathy
Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is the preferred diagnostic modality for evaluating mediastinal lymphadenopathy. However, its diagnostic yield is significantly reduced in conditions such as sarcoidosis, tuberculosis, and lymphoma. To address this limitation, EBUS-guided intranodal forceps biopsy (EBUS-IFB) has been proposed as an adjunct technique to enhance diagnostic accuracy in these challenging cases. This study aimed to evaluate the diagnostic yield of EBUS-IFB in the assessment of mediastinal lymphadenopathy. Methods: We retrospectively reviewed patients with mediastinal lymphadenopathy who underwent EBUS-guided intranodal forceps biopsy (EBUS-IFB). Diagnostic yield was determined using a composite reference standard (CRS), which was considered positive if a definitive diagnosis was established by any of the following: rapid on-site evaluation (ROSE), EBUS-TBNA, EBUS-IFB, bronchial biopsy, or transbronchial lung biopsy. To specifically evaluate the incremental diagnostic yield of EBUS-IFB, cases with non-diagnostic ROSE results were analysed separately. Results: Of the 40 cases with undiagnosed mediastinal lymphadenopathy, CRS was obtained in 31 cases (77.5%), while the remainder were diagnosed as reactive lymphadenopathy. Sampling adequacy was achieved in 39 out of 40 cases (97.5%). The overall diagnostic yield for EBUS-TBNA, EBUS-IFB, and combined EBUS-TBNA along with IFB (combined approach) were 54.8%, 83.9% (p value:0.03), and 90.3% (p value: 0.004) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 29.0% and 35.5% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity EBUS-IFB were 84% and 100% respectively. In subgroup analysis for cases with non-diagnostic ROSE, the diagnostic yield for EBUS-TBNA, EBUS-IFB, and the combined approach (EBUS-TBNA + IFB) were 48.2%, 85.2% (p value: 0.009) and 88.9% (p value: 0.003) respectively. The additional diagnostic yield for EBUS-IFB and the combined approach (EBUS-TBNA + IFB) were 37.0% and 40.7% respectively, as compared to EBUS-TBNA alone. The sensitivity and specificity of EBUS-IFB when ROSE was non-diagnostic were 85.2% and 100% respectively. No major complications were noted. Conclusion: The addition of IFB to routine TBNA significantly improves the diagnostic yield of EBUS, particularly in cases of non-diagnostic ROSE, with no added procedural complications.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5174
Weight loss on nintedanib therapy in interstitial lung diseases (ILD)
BACKGROUND: Nintedanib is an antifibrotic drug which slows down the progression of lung fibrosis in Idiopathic pulmonary fibrosis (IPF), Progressive pulmonary fibrosis (PPF) and Systemic Sclerosis ILD (SSc-ILD). Weight loss during Nintedanib therapy remains to be an understudied adverse drug effect, with no reports from India. Hence, we assessed its prevalence and significance in our ILD cohort. METHODOLOGY: Between July 2022 and Nov 2023, ILD patients seen in Pulmonary Medicine were screened retrospectively. Those on Nintedanib therapy with at least one follow-up visit were included in the study. Their clinico-demographics, physiology and treatment details were extracted from the electronic medical records. Weight loss on therapy was graded by the Common Terminology Criteria for Adverse Events (CTCAE) grade at 3, 6, 9 and 12 months of treatment. RESULTS: Out of 109 patients on Nintedanib, 61(56%) had a follow up. Of this 61 (57.4% males; mean age 57.69yrs±11.05; baseline weight 59.47kg±11.46; baseline FVC 1.64L±0.57), 34.4% were IPF and 57.4% were PPF. The mean weight loss at 3 months (n=38) was 0.94kg±2.88 (p<0.05), at 6 months (n=45) was 1.46kg±3.26 (p<0.05), at 9 months (n=8) was 2.37kg±4.03 and at 12 months (n=12) was 3kgs±5.9. The IPF and PPF cohorts had similar weight loss. At 6 months 17(37.8%) had significant weight loss. The baseline albumin level was significantly lower in the weight loss group (p<0.05). CONCLUSION: Weight loss is common during Nintedanib therapy but however, the mean weight loss in the Indian populace is lesser than in other published literature. The mean weight loss showed a serial rise with increasing duration. Further prospective studies are needed to find the associated risk factors.
- 14 September 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 64 (suppl 68) , PA5174
Weight loss on nintedanib therapy in interstitial lung diseases (ILD)
BACKGROUND: Nintedanib is an antifibrotic drug which slows down the progression of lung fibrosis in Idiopathic pulmonary fibrosis (IPF), Progressive pulmonary fibrosis (PPF) and Systemic Sclerosis ILD (SSc-ILD). Weight loss during Nintedanib therapy remains to be an understudied adverse drug effect, with no reports from India. Hence, we assessed its prevalence and significance in our ILD cohort. METHODOLOGY: Between July 2022 and Nov 2023, ILD patients seen in Pulmonary Medicine were screened retrospectively. Those on Nintedanib therapy with at least one follow-up visit were included in the study. Their clinico-demographics, physiology and treatment details were extracted from the electronic medical records. Weight loss on therapy was graded by the Common Terminology Criteria for Adverse Events (CTCAE) grade at 3, 6, 9 and 12 months of treatment. RESULTS: Out of 109 patients on Nintedanib, 61(56%) had a follow up. Of this 61 (57.4% males; mean age 57.69yrs±11.05; baseline weight 59.47kg±11.46; baseline FVC 1.64L±0.57), 34.4% were IPF and 57.4% were PPF. The mean weight loss at 3 months (n=38) was 0.94kg±2.88 (p<0.05), at 6 months (n=45) was 1.46kg±3.26 (p<0.05), at 9 months (n=8) was 2.37kg±4.03 and at 12 months (n=12) was 3kgs±5.9. The IPF and PPF cohorts had similar weight loss. At 6 months 17(37.8%) had significant weight loss. The baseline albumin level was significantly lower in the weight loss group (p<0.05). CONCLUSION: Weight loss is common during Nintedanib therapy but however, the mean weight loss in the Indian populace is lesser than in other published literature. The mean weight loss showed a serial rise with increasing duration. Further prospective studies are needed to find the associated risk factors.
- Open Access
- 28 January 2023
- Published by Mansa STM Publishers in Indian Journal of Case Reports
- p. 1-4
Presentations of pulmonary embolism in COVID-19: An Indian case series
The prevalence of pulmonary embolism (PE) among COVID-19 infections is significantly high. However, in resource-limited settings, appropriate computed tomography (CT) imaging is not possible for all COVID-19 patients. Very sick patients suspected of a PE may not be fit to be shifted to the CT room. Hence, it is likely that PE is underdiagnosed in Indian COVID-19 patients. Coexisting PE should be considered in all patients with influenza-like illnesses who have a Type 1 respiratory failure out of proportion to the severity of COVID- 19 radiology. In this case series, we discuss the different presentations of PE in patients with COVID-19.
- 28 January 2023
- Published by Mansa STM Publishers in Indian Journal of Case Reports
- p. 1-4
Open AccessPresentations of pulmonary embolism in COVID-19: An Indian case series
The prevalence of pulmonary embolism (PE) among COVID-19 infections is significantly high. However, in resource-limited settings, appropriate computed tomography (CT) imaging is not possible for all COVID-19 patients. Very sick patients suspected of a PE may not be fit to be shifted to the CT room. Hence, it is likely that PE is underdiagnosed in Indian COVID-19 patients. Coexisting PE should be considered in all patients with influenza-like illnesses who have a Type 1 respiratory failure out of proportion to the severity of COVID- 19 radiology. In this case series, we discuss the different presentations of PE in patients with COVID-19.
- Open Access
- 19 April 2022
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 6 (3) , 239-249
Treatment of COVID-19 Acute Respiratory Distress Syndrome With a Tabletop Noninvasive Ventilation Device in a Respiratory Intermediate Care Unit
- 19 April 2022
- Published by Elsevier in Mayo Clinic Proceedings: Innovations, Quality & Outcomes
- Vol. 6 (3) , 239-249
Open AccessTreatment of COVID-19 Acute Respiratory Distress Syndrome With a Tabletop Noninvasive Ventilation Device in a Respiratory Intermediate Care Unit
- Open Access
- 7 December 2021
- Published by Wiley in Respirology Case Reports
- Vol. 10 (1) , e0891
Recurrent COVID‐19 infection in a case of rituximab‐induced hypogammaglobulinaemia
Patients with immunodeficiency are at an increased risk of recurrent COVID‐19 infection. They may lack the natural immune response that usually confers long‐lasting immunity. Here, we present our experience managing one such patient, who had a COVID‐19 infection twice, 5 months apart. He had a positive SARS‐CoV‐2 real‐time reverse transcription polymerase chain reaction (RT‐PCR) and computed tomography (CT) thorax with classical findings of COVID‐19 on both occasions. He had multiple negative RT‐PCR tests and two CT scans without COVID‐19 features between these two infections. While the antibody response to the first infection was not detectable, the response to the second infection was robust. Live attenuated vaccines are contraindicated in patients with immunodeficiency, and other vaccines may not elicit an adequate immune response. A high index of suspicion for recurrent COVID‐19 is warranted in this group of patients.
- 7 December 2021
- Published by Wiley in Respirology Case Reports
- Vol. 10 (1) , e0891
Open AccessRecurrent COVID‐19 infection in a case of rituximab‐induced hypogammaglobulinaemia
Patients with immunodeficiency are at an increased risk of recurrent COVID‐19 infection. They may lack the natural immune response that usually confers long‐lasting immunity. Here, we present our experience managing one such patient, who had a COVID‐19 infection twice, 5 months apart. He had a positive SARS‐CoV‐2 real‐time reverse transcription polymerase chain reaction (RT‐PCR) and computed tomography (CT) thorax with classical findings of COVID‐19 on both occasions. He had multiple negative RT‐PCR tests and two CT scans without COVID‐19 features between these two infections. While the antibody response to the first infection was not detectable, the response to the second infection was robust. Live attenuated vaccines are contraindicated in patients with immunodeficiency, and other vaccines may not elicit an adequate immune response. A high index of suspicion for recurrent COVID‐19 is warranted in this group of patients.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA715
Short term treatment response in pulmonary sarcoidosis – a prospective study
Sarcoidosis is a multisystem granulomatous disease often involving lungs. Treatment response on steroids is not well studied particularly from India. We assessed this prospectively. To assess the short-term improvement of clinical, physiological, radiological and QOL parameters on steroid therapy treatment in pulmonary sarcoidosis. Consecutive patients newly diagnosed as pulmonary sarcoidosis by the ILD MDT were included. They received steroids as per BTS recommendations. Clinical (VAS cough score, MMRC for dyspnea, Fatigue assessment score), physiological (FVC, LV, DLCO), radiological (Obermeyer et al HRCT scoring) and QOL (Kings sarcoidosis questionnaire) parameters were assessed at baseline and after 3-4 months of therapy. Out of 55 patients recruited, 37(67%) of them came for follow-up. Others could not come due to the COVID pandemic. At 3-4 months of treatment, the change in VAS score for cough was -8.41(CI:-11.5,-4.88, P <0.001 ) and FAS scale was -8.4(CI:-11.95,-4.88, P <0.001). Spirometry showed an increase of mean FVC from 2.29 to 2.39 (p value<0.001). The total HRCT scoring reduced from 8.14 to 5.06 (p<0.001). Our study demonstrated significant short-term improvement in symptoms, lung functions, radiology and QOL after 3-4 months of treatment with steroids.
- 5 September 2021
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 58 (suppl 65) , PA715
Short term treatment response in pulmonary sarcoidosis – a prospective study
Sarcoidosis is a multisystem granulomatous disease often involving lungs. Treatment response on steroids is not well studied particularly from India. We assessed this prospectively. To assess the short-term improvement of clinical, physiological, radiological and QOL parameters on steroid therapy treatment in pulmonary sarcoidosis. Consecutive patients newly diagnosed as pulmonary sarcoidosis by the ILD MDT were included. They received steroids as per BTS recommendations. Clinical (VAS cough score, MMRC for dyspnea, Fatigue assessment score), physiological (FVC, LV, DLCO), radiological (Obermeyer et al HRCT scoring) and QOL (Kings sarcoidosis questionnaire) parameters were assessed at baseline and after 3-4 months of therapy. Out of 55 patients recruited, 37(67%) of them came for follow-up. Others could not come due to the COVID pandemic. At 3-4 months of treatment, the change in VAS score for cough was -8.41(CI:-11.5,-4.88, P <0.001 ) and FAS scale was -8.4(CI:-11.95,-4.88, P <0.001). Spirometry showed an increase of mean FVC from 2.29 to 2.39 (p value<0.001). The total HRCT scoring reduced from 8.14 to 5.06 (p<0.001). Our study demonstrated significant short-term improvement in symptoms, lung functions, radiology and QOL after 3-4 months of treatment with steroids.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Is smear microscopy obsolete in the era of Xpert MTB/Rif?
Background: Xpert MTB/RIF (Xpert), a cartridge based test has been a game changer in TB diagnosis with sensitivity of 97% in smear positive Pulmonary TB (PTB)and 74% in smear negative PTB, with a high specificity. It can also detect Rifampicin resistance. AFB smear microscopy (Smear) is an old technology, which has been the bedrock of PTB diagnosis in programmatic conditions. However its role has diminished with the advent of Xpert. The aim of this study is to assess the role of Smear, if Xpert is used as the first diagnostic test. Methods: We reviewed the results of all patients evaluated by the department of Pulmonary medicine, CMC, Vellore from 1 Jan 2018 to 31 Dec 2018, on whom sputum tests were ordered for the diagnosis of PTB. The following details were obtained from the electronic medical records of the hospital: clinical details, radiological features, results of Smear, Xpert, and Mycobacteria Culture (Culture). Results: In all 11,673sputum samplesof 5609 patients were tested. The tests performed were 8766 smears, 2485 Xpert and 422 cultures. A total of 2043 patients had Xpert test and at least 2 Smears.Both tests were positive in 190, Xpert alone in 199 and Smear alone in only 4(2 were non-tuberculous mycobacterial infection and 2 lost to follow up). In 409 patients who had Xpert and Culture of which 287 grew Mycobacterium Tuberculosis (MTB),the sensitivity of Xpert with culture as gold standard(GS) was 94% (271/287). A total of 421 patients had 2 Smears and Culture of which 302 grew MTB, sensitivity of Smear with Culture as GS was only 55% (168/302). Conclusion: Xpert yield was significantly higher than Smear, which did not add to yield. Xpert as the first diagnostic test could render Smear obsolete.
- 7 September 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (suppl 64)
Is smear microscopy obsolete in the era of Xpert MTB/Rif?
Background: Xpert MTB/RIF (Xpert), a cartridge based test has been a game changer in TB diagnosis with sensitivity of 97% in smear positive Pulmonary TB (PTB)and 74% in smear negative PTB, with a high specificity. It can also detect Rifampicin resistance. AFB smear microscopy (Smear) is an old technology, which has been the bedrock of PTB diagnosis in programmatic conditions. However its role has diminished with the advent of Xpert. The aim of this study is to assess the role of Smear, if Xpert is used as the first diagnostic test. Methods: We reviewed the results of all patients evaluated by the department of Pulmonary medicine, CMC, Vellore from 1 Jan 2018 to 31 Dec 2018, on whom sputum tests were ordered for the diagnosis of PTB. The following details were obtained from the electronic medical records of the hospital: clinical details, radiological features, results of Smear, Xpert, and Mycobacteria Culture (Culture). Results: In all 11,673sputum samplesof 5609 patients were tested. The tests performed were 8766 smears, 2485 Xpert and 422 cultures. A total of 2043 patients had Xpert test and at least 2 Smears.Both tests were positive in 190, Xpert alone in 199 and Smear alone in only 4(2 were non-tuberculous mycobacterial infection and 2 lost to follow up). In 409 patients who had Xpert and Culture of which 287 grew Mycobacterium Tuberculosis (MTB),the sensitivity of Xpert with culture as gold standard(GS) was 94% (271/287). A total of 421 patients had 2 Smears and Culture of which 302 grew MTB, sensitivity of Smear with Culture as GS was only 55% (168/302). Conclusion: Xpert yield was significantly higher than Smear, which did not add to yield. Xpert as the first diagnostic test could render Smear obsolete.